Raltegravir once daily or twice daily in previously untreated patients with HIV-1:A randomised, active-controlled, phase 3 non-inferiority trial

Autor: Eron, Joseph J., Rockstroh, Jurgen K., Jacques, Reynes, Jaime Andrade Villanueva, Jose Valdez Ramalho Madruga, Linda Gail Bekker, Benjamin, Young, Christine, Katlama, Jose Maria Gatell Artigas, Arribas, Jose R., Mark, Nelson, Havilland, Campbell, Jing, Zhao, Rodgers, Anthony J., Rizk, Matthew L., Larissa, Wenning, Miller, Michael D., Daria, Hazuda, Dinubile, Mark J., Randi, Leavitt, Robin, Isaacs, Robertson, Michael N., Peter, Sklar, Bach Yen Nguyen, Mezzaroma, Ivano, Italy, Rome

Publikováno v: Eron, J J, Rockstroh, J K, Reynes, J, Andrade-Villanueva, J, Ramalho-Madruga, J V, Bekker, L G, Young, B, Katlama, C, Gatell-Artigas, J M, Arribas, J R, Nelson, M, Campbell, H, Zhao, J, Rodgers, A J, Rizk, M L, Wenning, L, Miller, M D, Hazuda, D, DiNubile, M J, Leavitt, R, Isaacs, R, Robertson, M N, Sklar, P, Nguyen, B Y, Laursen, A L & QDMRK Investigators 2011, ' Raltegravir once daily or twice daily in previously untreated patients with HIV-1 : A randomised, active-controlled, phase 3 non-inferiority trial ', The Lancet Infectious Diseases, vol. 11, no. 12, pp. 907-915 . https://doi.org/10.1016/S1473-3099(11)70196-7
Lancet infectious diseases, 11(12), 907-915. Lancet Publishing Group

Background: Twice-daily raltegravir with once-daily tenofovir-emtricitabine is an effective initial antiretroviral regimen for patients with HIV-1. On the basis of pharmacokinetic data suggesting efficacy of once-daily raltegravir and because adheren

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72d45694a6e3952a234f3eea634809c3
https://pure.au.dk/portal/da/publications/raltegravir-once-daily-or-twice-daily-in-previously-untreated-patients-with-hiv1(6e27858b-c904-4f40-96e7-c40413c95477).html